Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Retrospective appraisal of busulfan dose adjustment in children

A Corrigendum to this article was published on 11 April 2003

Abstract

This report describes and critically appraises our experience with busulfan dose adjustment in children undergoing bone marrow transplant between April 1997 and March 1999. All children received an initial busulfan dose of 40 mg/m2 p.o. or by nasogastric tube. Whole blood samples were obtained 1, 1.5 and 6 h later and analyzed for busulfan content by gas chromatography with electron capture detection. The area under the whole blood busulfan concentration vs time curve (auc) and an individualized dose which would achieve an auc of 1300 μm/min were calculated. mean and median busulfan doses were calculated using actual, ideal and effective body weight and stratified according to age. the relationship between the busulfan concentration at hour 6 and auc was determined using linear regression. thirty-nine courses of busulfan were evaluated in 38 patients. a change from the initial busulfan dose was required to achieve the target auc in 34 courses (87%). most children >1 to 5 years old required dose increments while most children >5 years old required dose reductions. Obesity did not significantly affect busulfan dose requirements. Busulfan concentrations at 6 h only weakly predicted the AUC achieved (r2 = 0.496; P = 0.001). Based on these findings, we recommend that the initial busulfan dose be assigned according to patient age and actual body weight. We also recommend that busulfan AUC be calculated for children using a four-sample (1, 1.5, 4 and 6 h) limited sampling technique. Bone Marrow Transplantation (2000) 26, 1143–1147.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT Bone Marrow Transplant 1996 17: 225–230

    CAS  PubMed  Google Scholar 

  2. Ljungman P, Hassan M, Bekassy AN et al. High busulfan concentrations are associated with increased transplant-related mortality in allogenic bone marrow transplant patients Bone Marrow Transplant 1997 20: 909–913

    Article  CAS  Google Scholar 

  3. Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 1995 16: 31–42

    CAS  Google Scholar 

  4. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 1997 89: 3055–3060

    CAS  PubMed  Google Scholar 

  5. Bolinger AM, Zangwill AB, Slattery JT et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease Bone Marrow Transplant 2000 25: 925–930

    Article  CAS  Google Scholar 

  6. Chattergoon DS, Saunders EF, Klein J et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children Bone Marrow Transplant 1997 20: 347–354

    Article  CAS  Google Scholar 

  7. Dupuis LL, Armstrong C . Oral syringe for extemporaneously preparing doses Am J Health-Syst Pharm 1998 55: 735

    CAS  PubMed  Google Scholar 

  8. Gibaldi M . Biopharmaceutics and Clinical Pharmacokinetics, 4th edn Lea & Febiger: Philadelphia 1991 pp 377–378

  9. Haycock GB, Schwartz GJ, Wisotsky DH . Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults J Pediatr 1978 93: 62–66

    Article  CAS  Google Scholar 

  10. Traub SL, Kichen L . Estimating ideal body mass in children Am J Hosp Pharm 1983 40: 107–110

    CAS  PubMed  Google Scholar 

  11. Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability Blood 1994 84: 2144–2150

    CAS  PubMed  Google Scholar 

  12. Vassal G, Fischer A, Challine D et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease Blood 1993 82: 1030–1034

    CAS  PubMed  Google Scholar 

  13. Poonkuzhali B, Srivastava A, Querin MH et al. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation Bone Marrow Transplant 1999 24: 5–11

    Article  CAS  Google Scholar 

  14. Schuler U, Schroer S, Kühnle A et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994 14: 759–765

    CAS  PubMed  Google Scholar 

  15. Slattery JT, Risler LJ . Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation Ther Drug Monit 1998 20: 543–549

    Article  CAS  Google Scholar 

  16. Pawlowska AB, Blazar BR, Angelucci E et al. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia Bone Marrow Transplant 1997 20: 915–920

    Article  CAS  Google Scholar 

  17. Hassan M, Fasth A, Gerritsen B et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders Bone Marrow Transplant 1996 18: 843–850

    CAS  PubMed  Google Scholar 

  18. Vassal G, Deroussent A, Challine D et al. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992 79: 2475–2479

    CAS  PubMed  Google Scholar 

  19. Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology Cancer Chemother Pharmacol 1991 28: 130–134

    Article  CAS  Google Scholar 

  20. Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 1995 16: 31–42

    CAS  Google Scholar 

  21. Gibbs JP, Liacouras CA, Baldassano RN et al. Up-regulation of glutathione S-transferase activity in enterocytes of young children Drug Metab Dispos 1999 27: 1466–1469

    CAS  PubMed  Google Scholar 

  22. Gibbs JP, Gooley T, Corneau B et al. The impact of obesity and disease on busulfan oral clearance in adults Blood 1999 93: 4436–4440

    CAS  PubMed  Google Scholar 

  23. Kasai M, Kiyama Y, Watanabe M et al. Toxicity of high-dose busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation Transplant Proc 1992 24: 1529–1530

    CAS  PubMed  Google Scholar 

  24. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 1997 89: 3055–3060

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dupuis, L., Najdova, M. & Saunders, E. Retrospective appraisal of busulfan dose adjustment in children. Bone Marrow Transplant 26, 1143–1147 (2000). https://doi.org/10.1038/sj.bmt.1702700

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702700

Keywords

This article is cited by

Search

Quick links